Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PVX 410

Next Previous
X
Search
Drug Profile

PVX 410

Alternative Names: PVX-410; XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410

Latest Information Update: 05 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer AstraZeneca; Emory University; Massachusetts General Hospital; Merck Sharp & Dohme; OncoPep
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines; Peptides
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma; Triple negative breast cancer
  • Phase I/II Smoldering multiple myeloma

Most Recent Events

  • 09 Dec 2023 Efficacy and adverse events data from a phase I trial in Smoldering Multiple Myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 13 Jul 2023 Oncopep completes a phase-I trial in Triple-negative-breast-cancer(Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in USA (SC), prior to July 2023 (NCT03362060) (Oncopep pipeline, July 2023)
  • 13 Jul 2023 Oncopep completes a phase-I trial in Triple-negative-breast-cancer(Second-line therapy or greater, Adjuvant therapy, Monotherapy, Late-stage disease) in USA (IM), prior to July 2023 (NCT02826434) (Oncopep pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top